A new study has suggested regular use of aspirin might lower the risk of prostate cancer, Fox News reports.

The aspirin study is an analysis from the long-running Physicians' Health Study, a longitudinal trial at Brigham and Women's Hospital in Boston and the Harvard T.H. Chan School of Public Health.

However, a number of previous prostate-cancer studies have provided conflicting results on the preventive benefits of aspirin.

Researchers said that men who took at least three aspirin tablets a week reduced their risk of developing or dying from advanced prostate cancer.

Findings from the two studies were released Monday ahead of their presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco later this week.

According to the American Cancer Society estimates, about 220,000 cases of prostate cancer were diagnosed in the U.S. last year.

About 27,500 men died of prostate cancer in the year 2015.

For the study, the researchers used data from more than 22,000 men, out of which 3,193 were diagnosed with prostate cancer during a follow-up of 27 years. Of those cases, 403 had lethal cancer, which is defined as cancer that has metastasized or resulted in death, as reported by Pharmacist.

The study revealed that men who took aspirin regularly had a 24% lower risk of developing lethal cancer after being diagnosed with an early stage of the disease, and they had a nearly 40% lower risk of dying from prostate cancer.

However, the researchers noted that aspirin did not affect the incidence of the disease.